Cosmos Health Inc. is classed by the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries (industry code 5122), based in Thessaloniki, GR. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $65 million and a loss of $19 million (its filed statements).
Distribution businessWholesale-Drugs, Proprietaries & Druggists' SundriesThessaloniki, GRfilings since 20098 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a distribution business: prior from its industry code (SEC 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.5 out of ten, 8 of 9 metrics filed and 1 estimated: past 2.1 out of ten, present 4.8 out of ten, future 6.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 1.0 out of ten. 40 warning events since 2017; the latest 2026-08-14. 10th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.5 out of ten. +28.7% a year over 10 filed years; profitable in 1 of 10. 45th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.5 out of ten. CrossAssetData estimate 0.5/10, confidence 35 of 100 (one part). 5th percentile among 10 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 3.5 out of ten. ROE -104%: lost 104¢ per shareholder dollar. Leverage 72%: owes 72¢ per asset dollar. 35th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.5 out of ten. bottom 45% of 10 in its family; net margin -29.3%. 45th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 7.2 out of ten. top 28% of 9 in its family for leadership; chief executive since 2016. 72nd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.5 out of ten. top 45% of 10 in its family for room to expand. 55th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.1 out of ten. top 39% of 8 in its family for growth drivers. 61st percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.4 out of ten. top 36% of 7 in its family for expectations against reality. 64th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-04-15 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-18 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-10-09 for the period ended 2026-10-07 (on EDGAR). Newest filing: Form 8-K, 2026-10-09. Filings on record since 2009. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Wholesale 91%, Nutraceuticals and Pharmaceuticals 7%, Pharmamanufacturing 3%, Other under 1%. As tagged in its annual report (Form 10-K, filed 2026-04-15).
Who runs it
Siokas, Grigorios (Chief Executive Officer); Terzis, Georgios (Chief Financial Officer); Demetriades, Demetrios G. (Secretary); Aslidis, Anastasios (director); Bhutawala, Suhel (director); Hoidas, John James (director); Karkantzos, Theodoros Christos (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.